FOURTEENTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENTCredit Agreement • May 12th, 2017 • Xtant Medical Holdings, Inc. • Biological products, (no disgnostic substances) • New York
This FOURTEENTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) is made and entered into as of May 11, 2017 (the “Amendment Closing Date”) by and among Bacterin International, Inc., a Nevada corporation (the “Borrower”), ROS acquisition offshore lp, a Cayman Islands Exempted Limited Partnership (“ROS”), ORBIMED ROYALTY OPPORTUNITIES II, LP, a Delaware limited partnership (“Royalty Opportunities”), and, in their capacity as Guarantors under the Credit Agreement (as defined below), XTANT MEDICAL HOLDINGS, INC., a Delaware corporation (“Holdings”), X-SPINE SYSTEMS, INC., an Ohio corporation (“X-Spine” or the “Additional Delayed Draw Borrower”) and XTANT MEDICAL, INC., a Delaware corporation (“Xtant” and, along with Holdings and X-Spine, collectively, the “Guarantors”).
Aurora Management Partners Inc. 112 South Tryon St. Ste 1770 Charlotte, NC 28284 O: 704-377-6010 C: 828-638-5744 f: 828-324-6518 www.auroramp.comXtant Medical Holdings, Inc. • May 12th, 2017 • Biological products, (no disgnostic substances) • North Carolina
This letter along with the attached Schedules A and B (this “Agreement”) set forth the agreement between Xtant Medical Holdings, Inc. (the “Company”), on the one hand, and Aurora Management Partners Inc. (“Aurora”), on the other, (the Company and Aurora each, a “Party”) under which Aurora agrees to provide personnel to serve as the Company’s Chief Restructuring Officer, and, if the Company and Chief Restructuring Officer deem appropriate, Deputy Restructuring Officers.
